116 related articles for article (PubMed ID: 12131566)
1. Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator murabutide in HIV-1-infected patients.
Amiel C; De La Tribonnière X; Vidal V; Darcissac E; Mouton Y; Bahr GM
J Acquir Immune Defic Syndr; 2002 Jul; 30(3):294-305. PubMed ID: 12131566
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment.
Bahr GM; De La Tribonniere X; Darcissac E; Ajana F; Bocket L; Sissoko D; Yazdanpanah Y; Dewulf J; Amiel C; Mouton Y
J Antimicrob Chemother; 2003 Jun; 51(6):1377-88. PubMed ID: 12716777
[TBL] [Abstract][Full Text] [Related]
3. Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.
Bahr GM; Darcissac EC; Castéran N; Amiel C; Cocude C; Truong MJ; Dewulf J; Capron A; Mouton Y
J Virol; 2001 Aug; 75(15):6941-52. PubMed ID: 11435574
[TBL] [Abstract][Full Text] [Related]
4. The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.
Darcissac EC; Truong MJ; Dewulf J; Mouton Y; Capron A; Bahr GM
J Virol; 2000 Sep; 74(17):7794-802. PubMed ID: 10933686
[TBL] [Abstract][Full Text] [Related]
5. Clinical tolerance and profile of cytokine induction in healthy volunteers following the simultaneous administration of ifn-alpha and the synthetic immunomodulator murabutide.
Darcissac EC; Vidal V; Guillaume M; Thebault JJ; Bahr GM
J Interferon Cytokine Res; 2001 Sep; 21(9):655-61. PubMed ID: 11576459
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of a six-week cycle of immunotherapy with Murabutide in HIV-1 patients naive to antiretrovirals.
De La Tribonniere X; Mouton Y; Vidal V; Darcissac E; Sissoko D; Fontier C; Douadi Y; Dewulf Jl; Amiel C; Bahr GM
Med Sci Monit; 2003 Jun; 9(6):PI43-50. PubMed ID: 12824957
[TBL] [Abstract][Full Text] [Related]
7. Enhanced maturation and functional capacity of monocyte-derived immature dendritic cells by the synthetic immunomodulator Murabutide.
Vidal V; Dewulf J; Bahr GM
Immunology; 2001 Aug; 103(4):479-87. PubMed ID: 11529939
[TBL] [Abstract][Full Text] [Related]
8. Immune boosters. Murabutide--debut of a new immune booster?
TreatmentUpdate; 2003; 15(4):3. PubMed ID: 17216851
[No Abstract] [Full Text] [Related]
9. Murabutide revisited: a review of its pleiotropic biological effects.
Jakopin Ž
Curr Med Chem; 2013; 20(16):2068-79. PubMed ID: 23531213
[TBL] [Abstract][Full Text] [Related]
10. Differentially expressed genes in HIV-1-infected macrophages following treatment with the virus-suppressive immunomodulator murabutide.
Truong MJ; Delsart V; Bahr GM
Virus Res; 2004 Jan; 99(1):25-33. PubMed ID: 14687943
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects between recombinant interleukin-2 and the synthetic immunomodulator murabutide: selective enhancement of cytokine release and potentiation of antitumor activity.
Bahr GM; Darcissac E; Pouillart PR; Chedid LA
J Interferon Cytokine Res; 1996 Feb; 16(2):169-78. PubMed ID: 8742370
[TBL] [Abstract][Full Text] [Related]
12. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide.
Bahr GM
J Antimicrob Chemother; 2003 Jan; 51(1):5-8. PubMed ID: 12493780
[No Abstract] [Full Text] [Related]
13. Selective potentiation of cytokine expression in human whole blood by murabutide, a muramyl dipeptide analogue.
Darcissac EC; Bahr GM; Pouillart PR; Riveau GJ; Parant MA
Cytokine; 1996 Aug; 8(8):658-66. PubMed ID: 8894442
[TBL] [Abstract][Full Text] [Related]
14. Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens.
Audibert FM; Przewlocki G; Leclerc CD; Jolivet ME; Gras-Masse HS; Tartar AL; Chedid LA
Infect Immun; 1984 Jul; 45(1):261-6. PubMed ID: 6735468
[TBL] [Abstract][Full Text] [Related]
15. Reversal of T cell anergy in leprosy patients: in vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery.
Sridevi K; Khanna N; Chattree V; Pal PC; Haq W; Rao DN
Int Immunopharmacol; 2003 Nov; 3(12):1589-600. PubMed ID: 14555284
[TBL] [Abstract][Full Text] [Related]
16. A novel cellular RNA helicase, RH116, differentially regulates cell growth, programmed cell death and human immunodeficiency virus type 1 replication.
Cocude C; Truong MJ; Billaut-Mulot O; Delsart V; Darcissac E; Capron A; Mouton Y; Bahr GM
J Gen Virol; 2003 Dec; 84(Pt 12):3215-3225. PubMed ID: 14645903
[TBL] [Abstract][Full Text] [Related]
17. Influence of a muramyl dipeptide on human blood leukocyte functions and their membrane antigens.
Riveau GJ; Brunel-Riveau BG; Audibert FM; Chedid LA
Cell Immunol; 1991 Apr; 134(1):147-56. PubMed ID: 1707346
[TBL] [Abstract][Full Text] [Related]
18. Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide.
Bahr GM; Darcissac E; Bevec D; Dukor P; Chedid L
Int J Immunopharmacol; 1995 Feb; 17(2):117-31. PubMed ID: 7544767
[TBL] [Abstract][Full Text] [Related]
19. Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide.
Bahr GM; Pouillart PR; Chedid LA
J Interferon Cytokine Res; 1996 Apr; 16(4):297-306. PubMed ID: 9162523
[TBL] [Abstract][Full Text] [Related]
20. Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4.
Vidal VF; Castéran N; Riendeau CJ; Kornfeld H; Darcissac EC; Capron A; Bahr GM
Eur J Immunol; 2001 Jul; 31(7):1962-71. PubMed ID: 11449348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
